U.S. Markets closed

TrovaGene, Inc. (TROV)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.69-0.03 (-4.46%)
At close: 4:00PM EDT
People also watch
IDRASGYPBIOCVSTMSRNE
Interactive chart
Previous Close0.72
Open0.76
Bid0.70 x 500
Ask0.80 x 2000
Day's Range0.68 - 0.76
52 Week Range0.65 - 5.98
Volume235,674
Avg. Volume394,209
Market Cap21.37M
Beta0.67
PE Ratio (TTM)-0.52
EPS (TTM)-1.33
Earnings DateAug 2, 2017 - Aug 7, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Capital Cube5 hours ago

    ETFs with exposure to TrovaGene, Inc. : May 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TrovaGene, Inc. Here are 5 ETFs with the largest exposure to TROV-US. Comparing the performance and risk of TrovaGene, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Phase 1 Safety Study Supports Planned Development of PCM-075 in AML
    PR Newswire10 hours ago

    Phase 1 Safety Study Supports Planned Development of PCM-075 in AML

    SAN DIEGO, May 25, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced summary data from a phase 1 safety study conducted by Nerviano Medical Sciences with PCM-075, a polo-like kinase 1 (PLK1) inhibitor.  This data is supportive of a planned phase 1/2 clinical trial in patients with acute myeloid leukemia (AML) and is now being submitted for peer review publication by study investigators. The phase 1 safety study was an open-label, dose-escalation trial in patients with advanced or metastatic solid tumors.  PCM-075 was administered orally, once daily for five consecutive days, every day for three weeks, to evaluate drug metabolism and first cycle dose-limiting toxicities (DLTs) and related maximum tolerated dose (MTD).  The study also evaluated PCM-075's pharmacokinetic profile in plasma, its anti-tumor activity, and its ability to modulate intracellular targets in biopsied tissue.

  • TrovaGene, Inc. :TROV-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
    Capital Cubeyesterday

    TrovaGene, Inc. :TROV-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis TrovaGene, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of TrovaGene, Inc. – Genomic Health, Inc., Biocept, Inc., Laboratory Corporation of America Holdings, Exact Sciences Corporation, Quest Diagnostics Incorporated, PerkinElmer, Inc. and QIAGEN NV (GHDX-US, BIOC-US, LH-US, EXAS-US, DGX-US, ... Read more (Read more...)